Supplementary Table 1 Limiting dilution analysis of the frequency of LTRC-MLs in NOD/SCID mice injected with low-density lin^- $ALDH^+$ human cord blood cells

No. of cells per mouse	Positive mice/total after 20 weeks
10,000	3/4
8,000	1/1
3,000	1/3
1,000	2/4

NOD/SCID mice were injected with varying numbers of low-density lin^-ALDH^+ cord blood cells and 20 weeks later their marrows were assessed for the presence of both human B-lymphoid and human myeloid cells. The frequency of LTRC-MLs was determined from data pooled from 4 experiments as described in the Methods.

Supplementary Table 2 Limiting dilution analysis of the frequency of LTRC-MLs in the $CD133^+$ and $CD133^-$ subsets of low-density lin^-CD38^- $ALDH^+$ human cord blood cells

Subset of $CD38^-$ $ALDH^+$ cells injected	No. of cells per mouse	Positive mice/total after 20 weeks	LTRC-ML frequency (± SEM)
$CD133^+$	1950	5/6	1/1,100 (1/650 – 1/1,800)
$CD133^-$	1580	3/5	1/1,700 (1/1,000 – 1/3,100)

NOD/SCID mice were injected with matching isolates of $CD133^+$ and $CD133^-$ cells from the same pool of low-density lin^-CD38^- $ALDH^+$ cord blood cells and 20 weeks later their marrows were assessed for the presence of both lymphoid and myeloid human cells. The frequency of LTRC-MLs was determined as described in the Methods.

Supplementary Table 3 Limiting dilution analysis of the frequency of LTRC-MLs in the ALDH$^+$ subset of low-density lin$^-$ CD7$^-$ CD36$^-$ CD38$^-$ fraction of human cord blood cells

No. of cells per mouse	Positive mice/total after 20 weeks
4,000 3,000 1,000 500 400	4/4 3/3 5/5 7/10 2/3

NOD/SCID mice were injected with varying numbers of cells and 20 weeks later their marrows were assessed for the presence of both lymphoid and myeloid human cells. The frequency of LTRC-MLs was determined as described in the Methods. Mice were considered positive only if both human myeloid and human B-lymphoid cells were present. Data are pooled from 3 experiments.